Immunomedics:An International, Multi-Center, Doubl-Blind, Randomized, Phase III Trial 90Y-Clivatuzumab Tetraxetan +Low Dose Gemcitabine in Patients with Metastatic (StageIV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treat...

Project: Research

Status	Finished
Effective start/end date	05/26/15 → 03/28/18

Project Details